Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

AstraZeneca to Collaborate with SIBS on Cardiovascular Disease

publication date: Jan 28, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AstraZeneca and the Shanghai Institutes of Biological Sciences (SIBS) agreed to collaborate on a basic research project in cardiovascular disease. The two entities will seek to understand the development process for coronary vessels. The collaboration will focus on vessels that supply blood to the heart and will also attempt to regenerate the main branch to the heart. The ultimate goal of the project is to develop innovative treatments for cardiovascular disease. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...